Healthcare investment company NetScientific PLC (LON:NSCI) has invested a further US$500,000 in immunotherapeutic drug development company PDS Biotechnology.
The money will help fund the Phase II trials of PDS’s Versamune cancer treatment technology, following the successful Phase I trials back in April.
“The promising results from PDS’s Phase I results have provided positive validation of the Versamune T-cell activating platform technology,” said NetScientific chief executive Francois Martelet.
PDS operates within the immunotherapy field which is a hot topic in the healthcare world at the moment.
Immunotherapy involves harnessing the body’s own defence systems to help fight cancer and other infectious diseases.
Shares in NetScientific were down 1.4p, or 1.7%, to 78.6p.